Viatris Inc.

VTRS Healthcare Drug Manufacturers Specialty & Generic

Viatris Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, down 2.98% from fiscal 2024. In the quarter to June 2026, revenue grew 4.88%, EPS fell 2,464.1%, free cash flow grew 101.1% and total debt fell 18.1%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for five consecutive years.

18.66 0.44 +2.41%
Market cap
$20.9B
P/E
0.0×
Fwd P/E
61.1×
Dividend yield
2.57%
F-score
4/9
Altman Z
0.61
Beneish M
−3.29
Dividend safety
37/100

Viatris Inc. (VTRS) Free cash flow

Alert me on Free cash flow

Viatris Inc.'s free cash flow for fiscal 2025 was $1.9B, down 56.6% from $4.5B in fiscal 2024. Over the twelve months to 30 June 2026 it was $1.9B. Over the past ten years it has ranged from $552.7M (fiscal 2020) to $4.5B (fiscal 2024); the current reading is higher than 64% of that period. Viatris Inc. ranks 4th of 86 Drug Manufacturers Specialty & Generic companies by free cash flow.

Free cash flow, annual

Embed this chart

Annual newest first

Period Free cash flow Change
FY2025 $1.9B (56.58%)
FY2024 $4.5B 59.29%
FY2023 $2.8B 9.10%
FY2022 $2.6B 1.74%
FY2021 $2.5B 356.99%
FY2020 $552.7M (61.23%)
FY2019 $1.4B 21.29%
FY2018 $1.2B (6.37%)
FY2017 $1.3B (3.19%)
FY2016 $1.3B 13.83%

Quarterly newest first

Period Free cash flow Change
Jun 2026 $336.2M 25.45%
Mar 2026 $268.0M (58.15%)
Dec 2025 $640.4M (0.87%)
Sep 2025 $646.0M 286.36%
42 more quarters

Against its own ten years

Low $552.7M High $4.5B
Ten-year median $1.4B
Current reading's percentile 64

Free cash flow against peers

What Free cash flow is

Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.

Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)

The full definition of Free cash flow →

More on VTRS